PP Clarithromycin Kelas MoA Clarithromycin menghambat sintesis protein dengan menempel pada 50s ribosomal subunits.

Aktivitas melawan streptococci danstaphylococci dan spesies lain seperti B. catarrhalis, L. spp, C. trachomatis and U. urealyticum. Farmakokinetik Absorption: GI tract (oral). Distribution: Distribusi luas, ASI Metabolism: Hepatic dikonversi menjadi 14-hydroxyclarithromycin dan metabolit lain Excretion: via bile menjadi feses; via the urine (20-30% as unchanged, 10-15% as 14-hydroxyclarithromycin and other metabolites).3-4 hr and 5-7 hr (elimination half-life) Indikasi dan Dosis Oral Susceptible infections Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 714 days. Child: 7.5 mg/kg bid for 5-10 days. Oral Respiratory tract infections Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 714 days. Child: 7.5 mg/kg bid for 5-10 days. Oral Skin and soft tissue infections Adult: 250 mg bid increased to 500 mg bid for severe infections if necessary for 714 days. Child: 7.5 mg/kg bid for 5-10 days. Oral Mycobacterium avium complex infections Adult: 500 mg bid in combination with other antimycobacterials. Child: 7.5 mg/kg bid; to be used with other antimycobacterials. May increase dose to 15 mg/kg (max: 500 mg) bid. Oral Leprosy Adult: 500 mg daily as part of an alternative multidrug therapy. Oral Eradication of H. pylori associated with peptic ulcer disease Adult: 500 mg bid; given in combination with another antibacterial and either a proton pump inhibitor or H2-receptor antagonist for 7-14 days. Child: 1 yr: 7.5 mg/kg bid; may be given with another antibacterial and a proton Macrolides

pump inhibitor for 7 days. Intravenous Respiratory tract infections Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible. Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. Intravenous Skin and soft tissue infections Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible. Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. Intravenous Susceptible infections Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible. Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. Kontraindikasi Hypersensitivity. Patients receiving terfenadine, astemizole, pimozide, cisapride and ergot derivatives. Pregnancy; history of acute porphyria. Side Effect GI upset, glossitis, stomatitis, altered taste; headache, dizziness, hallucinations, insomnia, other CNS effects; rash; hepatic dysfunction, Potentially Fatal: Pseudomembranous colitis, anaphylaxis, Stevens-Johnson syndrome. Drug Interaction May potentiate oral anticoagulant action. May elevate serum-digoxin concentration. Potentially Fatal: Increases plasma concentrations of terfenadine or astemizole. Increases the risk of ventricular arrhythmias in patients with preexisting cardiac diseases. Special Precaution Renal and hepatic impairment; macrolide cross-resistance; lactation, children

Sumber : mims.com